A Beloved Classic Just Got Sweeter Than Ever; Candy Crush Solitaire™ Launches Worldwide
King, the interactive entertainment company behind the world-famous Candy Crush® franchise, today launches Candy Crush Solitaire™on mobile devices worldwide. Candy Crush Solitaire brings a fresh take to the classic card game, combining the timeless fun of solitaire with the vibrant and colorful world of Candy Crush.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250206977362/en/
Candy Crush Solitaire gameplay (Graphic: King)
Candy Crush Solitaire offers players a fun, mentally stimulating challenge, combining the familiar gameplay of TriPeaks solitaire with challenging levels, innovative gameplay, and tasty rewards, as they are immersed into the sensory and whimsical Candy Crush universe.
Beloved characters join players on a sweet journey around the world, collecting Candified postcards and delicious rewards as they progress through the game, solving puzzles and stacking cards. This new mobile game offering will launch with a set of features, including the “Hold Slot,” enabling players to set cards aside for later use, or they can unleash the fan-favorite Candy Color Bomb booster - reimagined in card form - to conquer tricky levels.
“We’re excited to take a timeless card game like solitaire and reimagine it through the lens of the iconic Candy Crush brand,” said Tjodolf Sommestad, President, King. “The launch of Candy Crush Solitaire marks an important step in King’s strategy to expand our portfolio by combining classic gameplay with our expertise in creating immersive, player-focused mobile experiences. This new addition not only strengthens the Candy Crush franchise’s global reach but also delivers fresh, innovative ways for players to connect and engage with the games they love, all with that signature Candy Crush energy.”
Candy Crush Solitaire builds on the success of Candy Crush Saga, the highest-grossing mobile game of all time in the Western world since its launch [source: Data.ai]. The game has maintained its relevance and reaffirmed its position as one of the global leaders in mobile gaming.
With Candy Crush first captivating players worldwide through Candy Crush Saga, the match-3 mobile gaming phenomenon, the franchise continues to evolve, boasting over 18,000 levels and now expanding into new genres to bring its iconic fun to even more players around the globe.
Since 2023, King has been part of the Microsoft family, and when asked about the most recent solitaire game, Paul Jensen, GM of Casual Games, Microsoft said, “As the most popular card game of all time, Microsoft solitaire is hugely special to us at Microsoft. We’re thrilled to see King create an exciting new twist to solitaire as the newest addition to King’s widely loved Candy Crush franchise. The launch marks an exciting milestone as our businesses look to work together to bring more choice and innovation to the mobile gaming market in the future.”
Candy Crush Solitaire is free to download and available now on the Amazon App Store, Apple App Store, Google Play, Samsung Galaxy Store and more.
About King
With a mission of Making the World Playful, King is a leading interactive entertainment company with more than 20 years of history of delivering some of the world’s most iconic games in the mobile gaming industry, including the world-famous Candy Crush franchise, as well as other mobile game hits such as Farm Heroes Saga. King games are played by more than 200 million monthly active users. King, part of Microsoft (NASDAQ: MSFT), has Kingsters in Stockholm, Malmö, London, Barcelona, Berlin, Dublin, San Francisco, New York, Los Angeles and Malta. More information can be found at King.com or by following us on LinkedIn, @lifeatking on Instagram, or @king_games on X.
About Candy Crush Solitaire
Candy Crush Solitaire™ brings a fresh twist to the classic card game, combining the timeless fun of solitaire with the vibrant and colorful world of Candy Crush®. Players can unwind and challenge themselves as they solve puzzles, stack cards, and enjoy innovative gameplay that reimagines solitaire in a delightful new way.
Candy Crush Solitaire is free to download and available on the Apple App Store, Google Play, and Amazon App Store. Whether you’re a fan of card games or looking for a relaxing escape, Candy Crush Solitaire offers a fun and engaging experience for players of all ages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250206977362/en/
Contacts
Global Media Contact: kingcomms@king.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category28.3.2025 15:22:00 EET | Press release
Altasciences, a nine-time CRO Leadership Award winner, is proud to announce they have been awarded a 2025 CDMO Leadership Award in the Small Molecule Dosage Form–North America category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327305519/en/ Altasciences receives a 2025 CDMO Leadership Award in the Small Molecule Dosage Form (North America) category. Altasciences’ CDMO site supports drug development with formulation, manufacturing, and analytical testing—from discovery to commercialization. Their FDA-inspected facility features Grade C cleanrooms, R&D and analytical labs, ICH stability chambers, and a cGMP warehouse. "This recognition reflects our CDMO team’s unwavering dedication and expertise, as well as our unrelenting commitment to advancing drug development in collaboration with leading pharmaceutical and biotech innovators,” says Marie-Hélène Raigneau, Co-Chief Operating Officer at Altasciences. “We are gratefu
SES and SpeQtral Sign MoU to Advance Global Quantum-Secure Communications28.3.2025 14:49:00 EET | Press release
SES and SpeQtral signed a Memorandum of Understanding (MoU) to develop an interoperable Optical Ground Station (OGS) to establish long-distance satellite-based Quantum Key Distribution (QKD) between Asia and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328851677/en/ SES's CEO Adel Al-Saleh and SpeQtral's CEO Chune Yang Lum sign a Memorandum of Understanding to develop an interoperable Optical Ground Station to establish long-distance satellite-based Quantum Key Distribution between Asia and Europe. Under the agreement, the development of an interoperable OGS will enable SES and SpeQtral to connect both companies’ current and future QKD satellite missions, resulting in easier access to, and diversity in the supply of long-distance QKD to end users in Asia, Europe and other future compatible ground stations worldwide. The integration of this proposed OGS with Singapore’s fibre-QKD network will help future customer
SBC Medical Group Holdings Inc. Announces Fourth Quarter and Full Year 2024 Financial Results28.3.2025 13:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical” or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for -the three months ended December 31, 2024 and full year 2024. Fourth Quarter 2024 Highlights Total revenues were $44 million, representing a 29% year-over-year decrease. Gross profit was $34 million, representing a 22% year-over-year decrease. Income from operations was $5 million, representing an 80% year-over-year decrease. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $21 million, representing a 22% year-over-year decrease. EBITDA margin1was 47% for the fourth quarter of 2024, compared to 43% for the fourth quarter of 2023. Net income attributable to SBC Medical Group was $7 million, representing a 54% year-over-year decrease. Earnings per share, which is defined as net inc
SINOVAC Announces New Board Member and Chairman of the Audit Committee28.3.2025 13:00:00 EET | Press release
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under Nasdaq Rule 5605, Mr. Borho has also been elected as the Chair of the Audit Committee of the Board. Mr. Borho is a founder and Managing Partner of OrbiMed and has over 30 years of experience investing in the healthcare sector. OrbiMed is a leading healthcare investment firm with approximately $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds and royalty/credit funds. OrbiMed funds have been shareholders of SINOVAC since 2013 and currently hold over 2.7 million shares. Following this appo
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta ® (pertuzumab) Biosimilar Candidate HLX1128.3.2025 12:00:00 EET | Press release
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for HLX11, an investigational biosimilar of Perjeta® (pertuzumab). Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer, and adjuvant treatment for certain HER2-positive early breast cancer, among other indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328881021/en/ The submission was based on a multicenter, randomized, double-blind, parallel-controlled phase 3 clinical study (NCT05346224) aimed to compare the efficacy and safety of HLX11 with reference Perjeta® (pertuzumab) as a neoadjuvant therapy in patients with HER2-positive, HR-negative early-stage, o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom